Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:activeDuring |
decitabine
|
| gptkbp:administrativeDivision |
once every 8 days
|
| gptkbp:chemicalFormula |
C8H10N4O4S
|
| gptkbp:clinicalTrials |
Phase II
Phase III improved overall survival hematological malignancies response rate of 30-50% |
| gptkbp:contraindication |
severe renal impairment
severe hepatic impairment hypersensitivity to decitabine |
| gptkbp:date |
2006-12-04
|
| gptkbp:dosageForm |
injection
|
| gptkbp:drugInterdiction |
antineoplastic agent
live vaccines azacitidine other myelosuppressive agents |
| gptkbp:firstAppearance |
gptkb:FDA
|
| gptkbp:formulation |
lyophilized powder
|
| gptkbp:gestationPeriod |
D
|
| gptkbp:hasAwards |
not recommended
|
| gptkbp:hasPopulation |
adults
pediatric patients |
| https://www.w3.org/2000/01/rdf-schema#label |
Dacogen
|
| gptkbp:impact |
up to 6 cycles
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count renal function tests |
| gptkbp:isOftenAccompaniedBy |
yes
|
| gptkbp:mandates |
gptkb:acute_myeloid_leukemia
chronic myelomonocytic leukemia |
| gptkbp:manufacturer |
gptkb:Astex_Pharmaceuticals
|
| gptkbp:marketedAs |
decitabine
|
| gptkbp:operates_in |
L01BC02
|
| gptkbp:packaging |
vial
|
| gptkbp:patentExpiration |
2023-12-04
|
| gptkbp:renovated |
with sterile water for injection
|
| gptkbp:route |
intravenous
|
| gptkbp:sideEffect |
anemia
fatigue nausea fever vomiting thrombocytopenia neutropenia increased risk of infection |
| gptkbp:storage |
store at 20-25°C
|
| gptkbp:triggerType |
DNA methyltransferase inhibitor
|
| gptkbp:usedFor |
treatment of myelodysplastic syndromes
|